|1.||Khazaeli, M B: 7 articles (10/2005 - 08/2001)|
|2.||Liu, Guozheng: 5 articles (01/2014 - 08/2007)|
|3.||Rusckowski, Mary: 5 articles (01/2014 - 08/2007)|
|4.||Dou, Shuping: 5 articles (01/2014 - 08/2007)|
|5.||Shen, Sui: 5 articles (10/2005 - 09/2002)|
|6.||Chen, Ling: 4 articles (01/2014 - 12/2008)|
|7.||Martin, Edward W: 4 articles (11/2013 - 10/2006)|
|8.||Hnatowich, Donald J: 4 articles (10/2011 - 08/2007)|
|9.||LoBuglio, Albert F: 4 articles (10/2005 - 09/2002)|
|10.||Hinkle, George H: 3 articles (11/2013 - 01/2010)|
07/15/1991 - "Although it has been suggested by cell culture studies, enhanced TAG-72 expression in human tumors under hormonal stimulation has not been described before."
07/01/2013 - "Although all four CARs were functionally active against the TAG-72 expressing tumor cells, the combination of CD3ζ, OX40, CD28 as well as the CH3-CH2-hinge-hinge domains most efficiently triggered T cell activation. "
06/01/2013 - "Considering their high specificity, reduced immunogenicity and multi-targeting behavior, these oligoclonal nanobodies represent a promising tool to target TAG-72 over-expressing tumor cells."
01/01/2013 - "Immunohistochemical examination and in vitro fluorescence imaging of the tumors showed that the CC49-QDs probe could bind TAG-72 expressed on MGC80-3 cells. "
10/01/2011 - "The A3-10 peptide, with lower, yet reasonable binding affinity compared with the A2-6 peptide, showed sufficiently favorable specific binding and tumor accumulation to be considered further as a potential imaging agent for TAG-72 positive cancers."
06/01/2010 - "Clinicopathological characteristics of the carcinomas and clinical outcome of the patients were associated with the TAG-72 expression. "
11/01/2008 - "The results suggest that the expression of TAG-72 may be an important feature of primary breast carcinomas. "
11/01/2008 - "Moreover, the survival rate of the patients with breast carcinoma expressing TAG-72 was significantly lower than the patients without TAG-72 expression (P<0.01). "
11/01/2008 - "Clinicopathological parameters of breast carcinoma and clinical outcome of the patients were associated with TAG-72 expression. "
11/01/2008 - "The positive rates of TAG-72 in breast carcinoma tissues were 78.81% (93/118). "
|3.||Colorectal Neoplasms (Colorectal Cancer)
07/01/1996 - "Immunohistochemical studies showed that TAG-72 is expressed in more than 80% of colorectal carcinomas, but is rarely expressed in normal epithelium and benign diseases. "
11/15/1996 - "TAG-72 expression was 5-fold higher in the normal mucosa from the colorectal carcinoma patients. "
11/15/1996 - "TAG-72 levels in normal colonic mucosa from healthy donors and patients diagnosed with colorectal cancer were compared. "
07/01/1996 - "Therefore, these data suggest that TAG-72 is a well suitable marker for colorectal cancer."
07/01/1996 - "The evaluation of TAG-72 in serum of colorectal carcinoma patients showed a sensitivity of approximately 40%, comparable to that of the widely used CEA. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
08/01/2007 - "Therapeutic efficacy of antibody-guided therapy for ovarian cancer treatment will be enhanced by the combined targeting of TAG-72, MUC1, and CA125."
11/01/1994 - "This study was performed to evaluate the clinical values of tumor-associated glycoprotein-72 serum levels alone or in combination with CA 125 in the diagnosis and monitoring of patients with ovarian cancer. "
08/01/2007 - "Among all ovarian cancer types, 72%, 61%, and 50% of the samples showed immunolabeling for TAG-72, MUC1, and CA125, respectively. "
06/28/2007 - "Immunoblot analysis demonstrated the expression of TAG-72 in three ovarian cancer cell lines (OVCAR3, SB247 and COV362.4). "
06/28/2007 - "We have also studied the expression of TAG-72 in ovarian cancer cell lines by confocal microscopy and immunoblot analyses. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/01/2005 - "This trial was designed to evaluate strategies to improve the efficacy of a radiolabeled monoclonal antibody (mCC49) against tumor-associated glycoprotein-72 (TAG-72) in patients with non-small cell lung cancer (NSCLC). "
06/01/1986 - "TAG-72 was shown to be expressed in several epithelial-derived cancers including 94% of colonic adenocarcinomas, 84% of invasive ductal carcinomas of the breast, 96% of non-small cell lung carcinomas, 100% of common epithelial ovarian carcinomas, as well as the majority of pancreatic, gastric, and esophageal cancers evaluated. "
|8.||Mucin-1 (CA 15-3 Antigen)
|9.||tumor-associated antigen 72
|1.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)